CD8A and neoplasm: In vivo depletion of CD4+ and CD8+ T cells simultaneously or CD8+ T cells alone partially reversed tumor growth inhibition induced by the combination of effective low-dose Anlotinib and anti-PD-1 therapy in EO771 tumors.